Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
Tango reports 82% tumor response rate in advanced pancreatic cancer trial
34 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 34 separate news trends connected to Pancreatic Cancer, spanning June 25, 2026 through October 23, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 281 article observations and 268 source signals, led by Health, Business, Entertainment coverage. Use it to compare how individual events emerged, spread and changed over time.
Tango reports 82% tumor response rate in advanced pancreatic cancer trial
A Phase 3 trial launches a new drug duo for RAS G12D pancreatic cancer amid low five‑year survival rates.
New pancreatic cancer drug approved, hailed as breakthrough in treatment.
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
A liquid‑biopsy blood test that spots 87% of early pancreatic cancers is sparking hype and regulatory debate.
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Pancreatic tumors hijack the blood clotting system to erect immune shields, prompting new strategies to breach their defenses.
FDA approval gives pancreatic cancer patients a new RAS‑targeted drug, but supply hurdles keep many waiting.
Newly approved pancreatic cancer drug may extend survival for lung cancer patients.
The FDA's approval of a $480,000-a-year pill for pancreatic cancer has sparked debate over the future of cancer drug pricing.
A new drug has been approved for pancreatic cancer, but it's not clear who will pay for it.
FDA’s August 26 approval of the first pancreatic‑cancer drug that extends survival sparks new hope for patients
The FDA has approved a new drug for pancreatic cancer, marking a significant milestone in treatment options.
A new pancreatic cancer drug that doubled survival time is now available to patients in Charleston.
Eight studies published on August 21, 2026, suggest new hope for patients with brain tumors and another deadly cancer
An experimental vaccine is generating immune responses against pancreatic cancer in high-risk individuals, according to early clinical findings.
Patients with pancreatic cancer are receiving a new pill treatment, marking a significant milestone in cancer therapy.
Patients in Illinois and Utah are among the first to receive a new experimental drug for pancreatic cancer.
Scientists are testing vaccines to intercept colon and pancreatic cancer before it starts
Medical advancements in pancreatic cancer treatment, specifically involving Daraxonrasib and RASolute-302 data, are expanding patient access in clinical settings.
18 news sources are covering this Entertainment story right now — Archynetys is tracking how fast it spreads.
A first-in-human trial for a mutant KRAS vaccine shows promise in preventing pancreatic cancer among high-risk patients.
A Johns Hopkins surgeon has highlighted an AI breakthrough capable of detecting pancreatic cancer before physicians can.
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
A vaccine targeting pancreatic cancer shows promise in preventing the disease in high-risk individuals.
5 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Medical discussions are intensifying over whether GLP-1 medications like Ozempic can prevent cancer or influence oncology recovery.
A new treatment for metastatic pancreatic cancer and KRAS-mutated cancers is generating optimism among experts and patients.
An experimental pill called daraxonrasib is showing promising early results and gaining regulatory attention for treating pancreatic cancer.
Medical experts are highlighting seven 'silent' symptoms of pancreatic cancer to improve early detection and awareness.
Researchers have discovered a drug that blocks 90% of pancreatic cancer cell migration in laboratory tests.
An experimental drug for pancreatic cancer is generating hope among medical professionals and patients.